Compare Novo Nordisk A/S (NVO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Sana Biotechnology Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Novo Nordisk A/S is far larger — about 252.4× Sana Biotechnology Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NVO | SANA | |
|---|---|---|
Market Cap | $220.53B | $873.84M |
Sector | Health | Health |
52-Week High | $71.70 | $5.92 |
52-Week Low | $35.29 | $2.68 |
Enterprise Value | $239.49B | $848.03M |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
